AFTAB, DANA T.,亚法特伯 达纳Ｔ,亞法特伯 達納Ｔ,YU, PEIWEN,于 沛文,亚法特伯 达纳T,亞法特伯 達納T,于 沛文
申请号：
TW104113427
公开号：
TW201622723A
申请日:
2015.04.27
申请国别(地区):
TW
年份:
2016
代理人:
摘要：
This invention is directed to the treatment of cancer in a patient, particularly a patient with lung adenocarcinoma, and more particularly a patient with SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer, with an inhibitor of MET, VEGFR2, and ROS1 which is a compound of Formula I: or a pharmaceutically acceptable salt thereof.本發明係針對利用MET、VEGFR2及ROS1抑制劑治療患者，特定言之患有肺腺癌之患者且更特定言之患有SLC34A2-ROS1、CD74-ROS1或FIG-ROS1融合陽性非小細胞肺癌之患者的癌症，該抑制劑為式I化合物：或其醫藥學上可接受之鹽。
